Back to search results

A Study of Eloralintide for Weight Loss in Type 2 Diabetes

This study is testing a drug called eloralintide to see if it can help people with overweight or obesity and type 2 diabetes lose weight. Researchers will compare eloralintide to a placebo (an inactive substance) to understand its effects. You may be able to join if you are an adult with type 2 diabetes, have a body mass index (BMI) of 27 or higher, and your diabetes treatment and weight have been stable. The main goal is to measure the percentage of body weight change from the start of the study to Week 64. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 1035 participants. It compares eloralintide to a placebo, both given as injections under the skin (SC).
What's involved
Your participation in the study will last about 75 weeks. The primary endpoint for measuring body weight change is at Week 64.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring body weight change is at Week 64, which is within the 75-week study duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Recruiting
PHASE3Ages 18+InterventionalTreatment
Eli Lilly and Company
~1,035 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:EloralintidePlacebo

At a glance

Recruiting sites
117 of 159 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Body Weight
Measured over Baseline, Week 64

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweightType 2 Diabetes Mellitus

Where it's being run

159 sites across 38 states
China16
Japan15
Argentina11
Florida10
California9
Spain9
Texas8
Poland8

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have type 2 diabetes
Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
Have a BMI ≥ 27 kg/m2
Have a stable body weight (\<5% body weight change) for 90 days prior to screening

Exclusion

Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
Have taken any of the following antihyperglycemic medications within 90 days before screening:
amylin analogs
glucagon-like peptide-1 (GLP-1) receptor agonists
glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
insulin
Have had within 90 days prior to screening:
heart attack
stroke
coronary artery revascularization
unstable angina, or
hospitalization due to congestive heart failure
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Have taken medications or alternative remedies intended for weight loss within 90 days of screening

What this trial measures

  • Percent Change from Baseline in Body WeightBaseline, Week 64